Drug intelligence / Profile preview

VYNT-010037

Development stage: Preclinical
Lead developer: Vyant Bio
Modality: Small Molecules

Overview

**VYNT-010037** is a preclinical small molecule drug developed by Vyant Bio (in collaboration with OrganoTherapeutics) as a **CDKL5 stimulant** targeting **CDKL5 Deficiency Disorder (CDD)**, a rare neurodevelopmental disorder caused by mutations in the CDKL5 gene leading to severe epilepsy and developmental delays. It aims to enhance CDKL5 activity to address the underlying neurological deficits. The program is also noted in contexts of neurodegenerative diseases therapeutics by Cyclica, though primary focus remains on CDD.[1][3][4]

Targets

CDKL5 (Cyclin-dependent kinase-like 5)

Beyond the preview

Go deeper on VYNT-010037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYNT-010037.

Explore the full profile